Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 (everolimus) in advanced pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy
2006-001247-64Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in islet cell tumor and pancreatic endocrine carcinoma (pNEC), sponsored by Novartis. Primary endpoint: Objective response rate. Started May 2006; status: completed.
02
Drugs
everolimus
03
Conditions
islet cell tumorpancreatic endocrine carcinoma (pNEC)
Beyond the preview
Go deeper on 2006-001247-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001247-64.